Physician profile
Mary S Mathis
NPI 1053446690
$2,571.01
in general payments reported to CMS, 2019-2025
15 companies · $649 in 2025
The $649 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.96 · 2022: $216 · 2023: $687 · 2024: $981 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,317.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,313.68 | 2021-2025 | |
| Novo Nordisk INC | $298.38 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $223.28 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $116.81 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $115.22 | 2024-2025 | Otezla, Repatha, Otezla |
| Viiv Healthcare Company | $107.00 | 2024 | |
| Pfizer INC. | $100.33 | 2023-2024 | |
| Exact Sciences Corporation | $65.00 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $53.21 | 2023-2025 | Breztri, Airsupra |
| Dynavax Technologies Corporation | $47.50 | 2024-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $47.36 | 2024 | Voquezna |
| Saluda Medical Americas, INC. | $28.95 | 2025 | Evoke |
| Dexcom, INC. | $22.47 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.02 | 2024 | Xifaxan |
| Medtronic, INC. | $13.80 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.